Acadia Pharmaceuticals (ACAD) PT Raised to $23 at Oppenheimer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Acadia Pharma (ACAD) Stock Soars on Positive Rett Syndrome Results, Analysts Still Not Convinced
December 7, 2021 8:17 AM ESTShares of Acadia Pharma (NASDAQ: ACAD) are up nearly 20% in pre-open Tuesday after the company reported positive top-line results from the pivotal Phase 3 study related to Rett syndrome.
The consistent efficacy across primary and key secondary endpoints in the Lavender study demonstrates the potential of trofinetide to treat Rett syndrome, said Kathie Bishop,... More
Acadia Pharmaceuticals (ACAD) PT Raised to $28 at Goldman Sachs
December 7, 2021 6:39 AM ESTGoldman Sachs analyst Salveen Richter raised the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $28.00 (from $25.00) while maintaining a Neutral rating.
... MoreAcadia Pharmaceuticals (ACAD) PT Raised to $26 at Mizuho Securities
December 7, 2021 6:30 AM ESTMizuho Securities analyst Vamil Divan raised the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $26.00 (from $24.00) while maintaining a Neutral rating.
The analyst commented, "Acadia has released top-line data for their pipeline asset trofinetide for the treatment of Rett syndrome. While... More
Acadia’s (ACAD) Rett Syndrome Data Adequate for Approval, Stock Gains Are Justified - Analyst
December 7, 2021 6:14 AM ESTOn December 6th, after market closed, Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced positive top-line results from the pivotal, Phase 3 Lavender study evaluating the efficacy and safety of trofinetide in 187 girls and young women aged 5-20 years with Rett syndrome.Acadia Pharma (NASDAQ: ACAD)
The... More
